Clinical trial results for
malignant pleural
mesothelioma
For adults with previously untreated malignant pleural mesothelioma (MPM) that cannot be removed by surgery
Clinical trial results for
malignant pleural
mesothelioma
For adults with previously untreated malignant pleural mesothelioma (MPM) that cannot be removed by surgery
Actor portrayals.
In a clinical trial of 605 people with previously untreated malignant pleural mesothelioma, 303 people were given OPDIVO + YERVOY, and 302 people were given platinum-based chemotherapy.
Half the people were alive
Half the people were alive
In the clinical trial, people given OPDIVO + YERVOY had a 26% lower risk of dying than those given platinum-based chemotherapy.
OPDIVO + YERVOY will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For adults newly diagnosed with malignant pleural mesothelioma (MPM) that cannot be removed by surgery
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of cancer that affects the lining of the lungs and chest wall called malignant pleural mesothelioma which cannot be removed by surgery.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.